Stock Financial Ratios

CASC / Cascadian Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.99
Volume990,200.00
Market Cap ($M)201.41
Enterprise Value ($M)65.88
Book Value ($M)74.36
Book Value / Share1.51
Price / Book4.05
NCAV ($M)64.45
NCAV / Share3.87
Price / NCAV4.88
Income Statement (mra) ($M)
Revenue0.00
EBITDA-64.83
Net Income-57.70
Balance Sheet (mrq) ($M)
Cash & Equivalents12.74
Cash / Share0.66
Assets0.00
Liabilities8.77
Quick Ratio7.35
Current Ratio7.35
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.78
Return on Assets (ROA)-0.69
Return on Equity (ROE)-0.78
Identifiers and Descriptors
CUSIP682324108
Central Index Key (CIK)1412067
Industry Groups
SIC 8731 - Commercial Physical and Biological Research
Other Related CUSIPS
14740B606
14740B956
14740B901
14740B906
147195101
14740B951
Share Statistics
Weighted Average Number Of Shares Outstanding Basic19,264,121
Common Shares Outstanding49,221,940
Weighted Average Number Of Diluted Shares Outstanding19,264,121
Common Stock Shares Outstanding22,562,640
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share2.10
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share0.26
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Minority Interest Per Share0.00
Liabilities Per Share0.46
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Cash Per Share0.66
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00

Related News Stories

Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian?

2018-02-18 seekingalpha
This M&A satisfied 50% of our criteria conducive to a buyout. For one, there is pipeline synergy. (107-0)

Merus: This ROTY Holding Flashed A Buy Signal

2018-02-16 seekingalpha
I remind readers of clinical catalysts that could serve to push shares higher, including safety and early activity mid-year for MCLA-117 in AML. (24-0)

Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update

2018-02-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (376-7)

Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates

2018-02-07 zacks
Seattle Genetics, Inc. (SGEN - Free Report) reported a loss of 41 cents per share for the fourth quarter of 2017, narrower than the Zacks Consensus Estimate of 43 cents but wider than the year-ago quarter loss of 39 cents per share. (47-0)

Seattle Genetics (SGEN) Q4 2017 Results - Earnings Call Transcript

2018-02-07 seekingalpha
Good day, ladies and gentlemen. Welcome to the Seattle Genetics Fourth Quarter and Year 2017 Financial Results Conference Call. Today's call is being recorded. (24-0)

CUSIP: 682324108